1. INTRODUCTION
===============

Intensity modulated radiotherapy ([imrt]{.smallcaps}) uses an optimized modulation of the beam fluences to generate complex dose distributions that are characterized by a high degree of conformity to the target volume and greater sparing of normal tissue. In the treatment of head-and-neck cancer, [imrt]{.smallcaps} is used mainly to preserve salivary function after radiotherapy [@b1-co13_3p108]--[@b4-co13_3p108] and to improve dose coverage for complexly shaped tumours located near critical structures [@b5-co13_3p108]--[@b7-co13_3p108]. In addition, because [imrt]{.smallcaps} allows a higher dose to be delivered to the macroscopic tumour than to the area at risk for microscopic disease within the same fraction, the [imrt]{.smallcaps} technique is ideally suited to the simultaneous delivery of integrated-boost accelerated fractionation schemes [@b8-co13_3p108],[@b9-co13_3p108].

Accounting for geometric uncertainties is an important issue with [imrt]{.smallcaps}, because the isodose lines conform tightly to the target volume. One approach to compensate for set-up errors, organ motion, and changes in target geometry consists of defining planning target volumes ([ptv]{.smallcaps}) for targets and planning organ-at-risk volumes ([prv]{.smallcaps}) for critical structures, as recommended by the International Commission on Radiation Units and Measurements ([icru]{.smallcaps}) [@b10-co13_3p108],[@b11-co13_3p108]. For the head-and-neck region, the safety margins included in the [ptv]{.smallcaps} are usually chosen to reflect expected setup uncertainties.

During treatment, portal imaging can be used to assess the accuracy of field alignment. However, acquiring port films for [imrt]{.smallcaps} is often impractical because of the complex modulation of the beam intensity. Thus, set-up verification for [imrt]{.smallcaps} usually consists of acquiring orthogonal images to check the isocentre localization. Verification methods that rely on this kind of two-dimensional imaging may not provide a comprehensive overview of all the geometric variations that can influence dose distribution in an [imrt]{.smallcaps} treatment. Slight variations in the patient's neck and shoulder positioning may not be properly assessed, and some significant changes in shape because of a patient's weight loss or tumour shrinkage may not be detected. Furthermore, the effects of these changes on the dose distribution are not as intuitive during treatment with [imrt]{.smallcaps} techniques. A proper [ptv]{.smallcaps} and [prv]{.smallcaps} definition for [imrt]{.smallcaps} should not only focus on the potential location of the target and the organs at risk during treatment, but should also integrate any geometric variation in the surrounding tissue that may result in significant deviation from the prescribed dose.

In the present study, we assessed the effect of geometric variations---including changes in patient anatomy and set-up uncertainties---on the target coverage and the dose to organs at risk by recalculating [imrt]{.smallcaps} dose distributions on repeat computed tomography ([ct]{.smallcaps}) scans taken during treatment. In addition, we generated [imrt]{.smallcaps} plans using 2.5-mm and 5.0-mm localization uncertainty margins to estimate the [ptv]{.smallcaps} and [prv]{.smallcaps} that would be effective in preventing significant underdosing of the target volume and overdosing of the critical structures.

2. PATIENTS AND METHODS
=======================

2.1 Patient Characteristics
---------------------------

We included 8 head-and-neck cancer patients consecutively treated with [imrt]{.smallcaps} at our institution in this dosimetric study. Primary tumour sites included oropharynx (4 patients), nasopharynx (2 patients), maxillary sinus (1 patient), and nodal metastasis from an unknown primary (1 patient). All patients had locally advanced stage [iii]{.smallcaps}--[iv]{.smallcaps}([a]{.smallcaps}) disease according to the 2002 American Joint Committee on Cancer classification. In 7 patients, the treatment volume consisted of comprehensive nodal irradiation (upper and lower neck nodes), and 1 patient received treatment to the primary tumour site and upper neck region only. Two patients also received concurrent chemotherapy with cisplatin.

2.2 CT Scans
------------

Two weeks before the start of treatment, all patients first underwent [ct]{.smallcaps} simulation in the treatment position. To ensure proper immobilization and treatment reproducibility, custom-made thermoplastic face masks and shoulders pulls were used. The slice thickness of the [ct]{.smallcaps} scan was 5 mm through the entire head and neck region. Each patient then underwent repeat [ct]{.smallcaps} scans at weekly intervals during treatment, with the goal of obtaining at least four [ct]{.smallcaps} scans per patient. However, because of severe weight loss (3 patients) or significant shrinkage of a large neck mass (1 patient), some patients required a new mask during the course of treatment. In each of these cases, a new [imrt]{.smallcaps} plan was generated for the remainder of the treatment. As a result, only the repeat [ct]{.smallcaps} scans that were made with the initial mask were used for the study. Thus, 4 patients had four repeat [ct]{.smallcaps} scans as planned, 2 patients had three [ct]{.smallcaps} scans, and 2 patients had two [ct]{.smallcaps} scans, for a total of 26 repeat [ct]{.smallcaps} scans. All the repeat [ct]{.smallcaps} scans were acquired using the same [ct]{.smallcaps} protocol that was used in the planning [ct]{.smallcaps} scans and radio-opaque markers were placed on the thermoplastic masks to indicate the treatment isocentre.

2.3 Contouring Target Volumes and OAR
-------------------------------------

The gross tumour volume ([gtv]{.smallcaps}), clinical target volume ([ctv]{.smallcaps}), and organs at risk ([oar]{.smallcaps}s) were contoured on the initial planning [ct]{.smallcaps} scan according to [icru]{.smallcaps} definitions. The primary tumour and each positive node were delineated as separate volumes, except when they were immediately adjacent. The [ctv]{.smallcaps} was defined as any potential area of microscopic disease and usually included a margin of at least 1 cm around the [gtv]{.smallcaps} to account for direct tumour invasion (except when it was adjacent to structures known not to be involved), plus the lymph-node regions at risk. For dose prescription and [dvh]{.smallcaps} analysis, the upper and lower nodal neck regions were contoured separately. The normal structures that were defined were the spinal cord and brain stem, the ipsilateral and contralateral parotids, the mandible, and the larynx. The target volumes ([gtv]{.smallcaps} and [ctv]{.smallcaps}) and [oar]{.smallcaps}s were then redrawn on all the repeat [ct]{.smallcaps} scans by a single radiation oncologist. An anatomy-matching fusion algorithm semiautomatically matched the original with the repeat CT scans so that the original targets were superimposed on the repeat CT scans. The target contours were then modified with respect to changes in patient anatomy.

2.4 IMRT Treatment Planning
---------------------------

The [ct]{.smallcaps} images and radiotherapy structures were transferred from the initial planning [ct]{.smallcaps} scans to an inverse planning system (Corvus 5.0: Nomos Corporation, Sewickley, PA, U.S.A.), and [imrt]{.smallcaps} plans were generated using 7--9 equally spaced 6-MV photon beams. The prescribed dose was 66--70 Gy to the [gtv]{.smallcaps}s, 54--60 Gy to the upper neck [ctv]{.smallcaps}, and 54 Gy to the lower neck [ctv]{.smallcaps}, planned for delivery in a single phase using fractions of 1.6--2 Gy for the [ctv]{.smallcaps}s and 2.12--2.4 Gy for the [gtv]{.smallcaps}s. The planning goal was to provide adequate target coverage (prescription isodose encompassing at least 95% of each target) while limiting the dose to the [oar]{.smallcaps}s (spinal cord: \<45 Gy; brain stem: \<54 Gy; parotid mean dose: \<26 Gy).

For each patient, three [imrt]{.smallcaps} plans were generated: one with no margins for localization uncertainty, and two with margins (2.5-mm, 5.0-mm) around the [gtv]{.smallcaps} and [ctv]{.smallcaps} (resulting in [ptv]{.smallcaps}s) and around the spinal cord and brain stem ([prv]{.smallcaps}s). No margins were added around the parotids and the other [oar]{.smallcaps}s.

2.5 Recalculation of Dose Distributions and Analysis
----------------------------------------------------

The beam configurations and intensity profiles of the initial [imrt]{.smallcaps} plans generated from the planning [ct]{.smallcaps} scans were then applied on each repeat [ct]{.smallcaps} scan. The radio-opaque fiducials placed on the thermoplastic mask were used for isocentre alignment. Dose distributions were recalculated, and dose--volume histograms ([dvh]{.smallcaps}s) were generated for the targets and [oar]{.smallcaps}s. To assess dose coverage, the dosimetric parameters that were analyzed included the percentage of the [ptv]{.smallcaps} that received at least 100% and 95% of the prescribed dose (V~100~, V~95~). In addition, the lowest dose to 1% of the target volume, which can also be defined as the dose delivered to at least 99% of the volume (D~99~), was used to monitor for cold spots inside the target volume.

For the spinal cord and brain stem, the maximum dose (D~max~) and the highest dose to a volume of 1 cm^3^ (D~1cm3~) were analyzed. The mean doses (D~mean~) to the ipsilateral and contralateral parotids were used to assess parotid sparing, and the D~mean~ to the larynx, plus the D~1cm3~ to the mandible were also recorded.

3. RESULTS
==========

3.1 Analysis of the Target Coverage
-----------------------------------

[Table I](#ti-co13_3p108){ref-type="table"} summarizes the analysis of the target coverage for the initial [imrt]{.smallcaps} plans and for the recalculated dose distributions from the repeat [ct]{.smallcaps} scans. Note that, for the initial [imrt]{.smallcaps} plans, the values reported are for the [ptv]{.smallcaps}s generated with 0-mm, 2.5-mm, and 5.0-mm uncertainty margins, and for the repeat [ct]{.smallcaps} scans, values are for the [gtv]{.smallcaps}s and [ctv]{.smallcaps}s.

### 3.1.1 Initial IMRT Plans

The coverage of the [ptv]{.smallcaps}s as assessed by the mean values of V~100~ and V~95~ was similar for the initial [imrt]{.smallcaps} plans generated without any margins and for plans with 2.5-mm and 5.0-mm margins. However, the mean value of D~99~ was lower for the upper- and lower- neck [ptv]{.smallcaps}s when 5-mm margins were used. This difference probably arose because portions of these larger [ptv]{.smallcaps}s overlapped with the surrounding normal structures (such as the parotid glands), resulting in a compromise in target coverage to achieve adequate organ sparing. In addition, the [ptv]{.smallcaps}s generated by adding 5.0-mm margins around the nodal-region [ctv]{.smallcaps}s frequently extended into the build-up region close to the skin surface, where the calculated dose may be lower.

### 3.1.2 Repeat CT Scans

Overall, when no localization uncertainty margins were added at the time of planning, the mean values of V~100~, V~95~, and D~99~ were significantly lower for the repeat [ct]{.smallcaps} scans than for the initial [imrt]{.smallcaps} plans. The dose coverage improved for all target volumes when [ptv]{.smallcaps}s were generated. Most of the benefit was seen with the use of the 2.5-mm margins; the 5.0-mm margins resulted in modest further improvement. The rate of adequate target coverage, as defined by the proportion of targets with a V~100~ greater than or equal to 95% also improved with the use of [ptv]{.smallcaps}s. When no margins were added for uncertainty, only 12% of the [gtv]{.smallcaps}s, 54% of the upper-neck [ctv]{.smallcaps}s, and 25% of the lower-neck [ctv]{.smallcaps}s had a V~100~ ≥ 95%. With the use of 2.5-mm and 5.0-mm margins, this proportion increased to 87.5% and 97.5% for the [gtv]{.smallcaps}s, and to 97.1% and 100% for the upper-neck [ctv]{.smallcaps}s respectively. However, with the 2.5-mm and 5.0-mm margins alike, only 72.7% of the lower-neck [ctv]{.smallcaps}s were adequately covered by the prescription isodose. This result reflects significant variation in shoulder position at the time of the repeat [ct]{.smallcaps} scan from the position at the initial planning [ct]{.smallcaps} scan. As shown in [Figure 1](#f1-co13_3p108){ref-type="fig"}, the elevation of the shoulder on the [ct]{.smallcaps} scan acquired during week 2 caused a major change in the shape of the external contour at that level, resulting in increased attenuation of the oblique beams. However, the impact of positioning errors on coverage by the 95% isodose was not as pronounced, and when 5.0 mm margins where used, the V~95~ for the lower-neck [ctv]{.smallcaps} was greater than or equal to 95% in all cases.

3.2 Analysis of the Dose to the OARs
------------------------------------

[Table II](#tii-co13_3p108){ref-type="table"} summarizes the analysis of the dose to the [oar]{.smallcaps}s for the initial [imrt]{.smallcaps} plans and of the recalculated dose distributions from the repeat [ct]{.smallcaps} scans. Note that, for the initial [imrt]{.smallcaps} plans, the values of D~max~ and D~1cm3~ for the spinal cord and brain stem are for the [prv]{.smallcaps}s generated with 0-mm, 2.5-mm, and 5.0-mm localization uncertainty margins; for the repeat [ct]{.smallcaps} scans, the values are for the anatomic structures only.

### 3.2.1 Initial IMRT Plans

The average D~max~ to the spinal cord and brain stem [prv]{.smallcaps}s was slightly above the specified limit for the initial [imrt]{.smallcaps} plans generated with 2.5-mm and 5.0-mm localization uncertainty margins. However, the dose to the anatomic structures (without margins) was below 45 Gy for the spinal cord and 54 Gy for the brain stem in all plans.

Unsurprisingly, the D~mean~ to the parotids and larynx, and the D~1cm3~ to the mandible increased when 2.5-mm and 5.0-mm margins were added around the target volumes to generate [ptv]{.smallcaps}s.

### 3.2.2 Repeat CT Scans

The D~max~ to the spinal cord was greater than 45 Gy in 57% of repeat [ct]{.smallcaps} scans when no [prv]{.smallcaps} was used, as compared with 35% with 2.5-mm margins and 15.4% with 5.0-mm margins. However, the D~max~ to the brain stem was above 54 Gy in only 3.8% of the cases when no [prv]{.smallcaps} was generated and in 7.8% of the cases when 2.5-mm and 5.0-mm margins were added. A possible explanation is that the [prv]{.smallcaps}s were generated only when similar margins were also added for the [ptv]{.smallcaps}. Because of the narrower separation between the target volume and the brain stem when 2.5-mm and 5.0-mm margins were added, the 54 Gy isodose was closer to the brain stem for the plans with [ptv]{.smallcaps} and [prv]{.smallcaps} than for the plans with no margins. The highest D~1cm3~ to both the spinal cord and the brain stem were below 45 Gy and 54 Gy, respectively, for all repeat [ct]{.smallcaps} scans.

The D~mean~ to the parotids and larynx and the D~1cm3~ to the mandible were also higher for the recalculated dose distributions than for the [imrt]{.smallcaps} plans. The average increase in the D~mean~ was 1--1.5 Gy for the contralateral parotid, but 2--3 Gy for the ipsilateral parotid. The magnitude of the increase was similar for all plans whether generated with 0-mm, 2.5-mm, or 5.0-mm localization uncertainty margins.

4. DISCUSSION
=============

As compared with conventional portal images, [ct]{.smallcaps} scan imaging for treatment verification provides a more accurate representation of the geometric variations that occur during a course of head-and-neck [imrt]{.smallcaps}, including uncertainties in patient position, isocentre localization, organ motion, and changes in external contour because of weight loss or tumour shrinkage. The anatomic information from the [ct]{.smallcaps} scan can also be used to generate three-dimensional (3-D) dose distributions to estimate with greater accuracy the dose delivered to the targets and the critical structures during a fractionated course of [imrt]{.smallcaps}. However, such evaluation is labour-intensive and not without inconveniences.

First, delineation of target volumes and [oar]{.smallcaps}s may not be identical for the treatment planning [ct]{.smallcaps} scan and each of the repeat [ct]{.smallcaps} scans acquired during treatment. A recent study by Barker *et al.* [@b12-co13_3p108] showed that the [gtv]{.smallcaps}s decreased in size throughout the course of treatment at a median rate of nearly 2% per treatment day. Contouring variations or changes in tumour shape or size may thus influence the [dvh]{.smallcaps}s for these structures.

In our study, image-fusion techniques and standardized target volume definitions based on well-defined anatomic landmarks [@b13-co13_3p108],[@b14-co13_3p108] were used to minimize contouring discrepancies between the initial planning [ct]{.smallcaps} scan and the repeat [ct]{.smallcaps} scans. As shown in [Table III](#tiii-co13_3p108){ref-type="table"}, only small variations in the size of the [gtv]{.smallcaps}s and [ctv]{.smallcaps}s occurred, except in the case of a few positive nodes that shrank during treatment. Also, the use of dosimetric parameters alone to assess target coverage and organ sparing may not be sufficient for [imrt]{.smallcaps} dose distributions. Analyzing [dvh]{.smallcaps}s does not give information about whether an area of lower dose is localized in the periphery or in the central region of the target volume, or if an area of higher dose represents a clinically significant hot spot within a critical structure or instead consists of multiple hot foci of negligible size. In addition, it is impossible to tell if areas of dose perturbation are always located at the same place on each of the [ct]{.smallcaps} scans.

However, despite these limitations, the use of [ct]{.smallcaps} imaging together with 3-D dosimetric analysis constitutes an effective method to study the effects of geometric uncertainties on the dose.

Adding margins for localization uncertainty at the time of treatment planning can effectively reduce the hazardous effect of these variations on target coverage and dose to critical structures. However, the addition of margins may not compensate completely for dose perturbation caused by a significant change in external contour.

In fact, redesign or modification of the [ptv]{.smallcaps} cannot compensate for the underdosing in the lower neck region observed when the shoulders were not properly repositioned at the time of the repeat [ct]{.smallcaps} scan. The effect of less radical changes in the shape of the external contour, such as those related to weight loss or tumour shrinkage, are probably not as important. A dosimetric study by Kim *et al.* [@b15-co13_3p108] showed that expansion and contraction of the external contour by 5 mm in all directions for a head-and-neck [imrt]{.smallcaps} plan does not result in significant dose perturbation for the tumour and critical structures.

Our results also suggest that the amplitude of the [ptv]{.smallcaps} required to assure ideal target coverage during treatment may vary, depending on target volume location, size, and shape. In our study, adding 2.5-mm localization uncertainty margins appeared sufficient to provide good target coverage more than 95% of the time (V~100~ ≥ 95%) for the upper neck [ctv]{.smallcaps}; 5.0-mm margins were required to achieve the same level of coverage for [gtv]{.smallcaps}s. This finding may be explained by the fact that a given set-up error---a 3-mm misalignment of the isocentre, for example---will have a greater influence on the target coverage (as assessed by the V~100~) for a positive lymph node measuring 1 cm than for the entire upper-neck region. In addition, set-up accuracy is rarely uniform through the whole treatment volume; the importance of the geometric uncertainty may vary depending on the location of the target.

In a study by Gilbeau *et al.* [@b16-co13_3p108], reproducibility of the set-up was found to be significantly worse at the level of the shoulder with the use of a thermoplastic mask that covers the head only. A similar observation was made by Garg *et al.* [@b17-co13_3p108], who reported that, despite custom immobilization, the curvature of the cervical spinal changes during the course of treatment, and set-up reproducibility was inferior for isocentres located in the low-neck region. Additional margins for organ motion may also be required for tumours involving the base of the tongue or the larynx [@b18-co13_3p108], but such margins are probably unnecessary for a nasopharyngeal tumour.

Proper [ptv]{.smallcaps} margins should not only focus on target coverage, but also consider the effect on normal-tissue sparing. Our results showed that the D~mean~ to the parotids and larynx increases when larger margins are added for [ptv]{.smallcaps} at the time of planning. Similar observations have also been made by van Asselen *et al.* [@b19-co13_3p108], who reported that the use of large [ptv]{.smallcaps} margins reduces parotid sparing and increases the normal-tissue complication probability for xerostomia. Geometric variations between the planning [ct]{.smallcaps} scans and the repeat [ct]{.smallcaps} scans also seem to influence the mean dose to the parotids in a similar manner, with the greater increase being observed when 5.0-mm localization uncertainty margins are added around the upper-neck [ctv]{.smallcaps}. Manning *et al.* [@b20-co13_3p108] proposed the use of a [prv]{.smallcaps} for the contralateral parotid to compensate for the detrimental effect of the geometric variation on parotid sparing. Their work suggests that 5.0-mm margins were effective in preventing the increase in the contralateral parotid volume irradiated to 30 Gy when the isocentre was shifted toward that side.

In addition to physical position uncertainties, other geometric variations, such as changes in the volume of the glands during treatment, may also influence the dose delivered to the parotids. In the study by Barker *et al.* [@b12-co13_3p108], the parotid glands decreased in volume with time, at a rate of 0.6% per day, and the centre of the glands shifted medially because of the weight loss that occurred during treatment. Thus, simply adding [prv]{.smallcaps} margins around the parotids may not compensate properly for the overall effect of geometric uncertainties on the D~mean~ to the parotids. Moreover, in the study by Manning *et al.* [@b20-co13_3p108], the use of 5-mm [prv]{.smallcaps} margins around the contralateral parotids resulted in decreased coverage of the nodal region adjacent to the parotids. To avoid this problem and to limit planning complexity, we consider that [prv]{.smallcaps} should be used only for structures such as the brain stem and spinal cord, for which the consequence of overdosing may be serious.

In the present study, the selection of 2.5-mm and 5.0-mm margins was based mainly on the range of the set-up errors reported for head-and-neck cancer patients treated with custom immobilization devices [@b15-co13_3p108],[@b16-co13_3p108],[@b21-co13_3p108]--[@b26-co13_3p108]. Our results suggest that these margins appear to give satisfactory target coverage, but care must be taken when generalizing about required margins for [ptv]{.smallcaps} and [prv]{.smallcaps}. Because the repeat [ct]{.smallcaps} scans were not acquired with the patient lying on the treatment couch, this study did not assess some of the mechanical uncertainties inherent to [imrt]{.smallcaps} treatment delivery. Thus, we cannot assume that the variations in set-up between the planning [ct]{.smallcaps} and each repeat [ct]{.smallcaps} scan are truly representative of those encountered at the treatment machine. Uncertainties in couch and gantry geometry or in alignment of the lasers relative to the treatment machine isocentre may effectively introduce systematic errors between the [ct]{.smallcaps} planning and treatment machine set-up [@b27-co13_3p108]. The integrated [ct]{.smallcaps}/[linac]{.smallcaps} unit [@b28-co13_3p108],[@b29-co13_3p108] now allows for 3-D imaging verification at the treatment machine, and such systems may be used for future investigations.

Our study did not address the issue of the intrafractional variations attributable to patient and internal-organ motion. However, in a study by Lee *et al.* [@b30-co13_3p108], 20 patients undergoing [imrt]{.smallcaps} for head-and-neck cancer had a set of orthogonal portal images taken before and after each fraction of radiotherapy for 3 consecutive days. Overall, the magnitude of intrafraction patient motion was minimal (x axis: 0.4 mm + 1.2 mm; y axis: 1.2 mm + 1.6 mm; z axis: --0.6 mm + 1.2 mm), and no persistent intrafraction motion was observed. In another study using an infrared camera monitoring system, Kim *et al.* [@b31-co13_3p108] also found that intrafraction positioning uncertainty was less than 2 mm for head-and-neck cancer patients treated with [imrt]{.smallcaps}. Based on these results, intrafraction patient motion does not seem to differ significantly from interfraction set-up uncertainty.

Finally, our results are based on a relatively low number of repeat [ct]{.smallcaps} scans per patient (median: 3). For that reason, [dvh]{.smallcaps}s from the 26 [ct]{.smallcaps} scans obtained for the 8 patients were pooled to assess target coverage and dose to [oar]{.smallcaps}s. This population-based approach may not reflect recurrent systematic deviations in some patients [@b32-co13_3p108]. In our study, 2 patients had repeated errors in the positioning of the shoulder, which caused underdosing of the lower neck region; coverage for the other patients was adequate when 2.5-mm and 5.0-mm margins were used. Additionally, because only the repeat [ct]{.smallcaps} scan acquired with the same mask and immobilization system as that used for the initial planning [ct]{.smallcaps} scan were included in our analysis, we cannot presume that our findings apply to patients with severe weight loss or tumour shrinkage that produces changes in the surrounding tissue important enough to affect the quality of the immobilization. At our institution, a new mask is made whenever the mask does not fit properly or the isocentre does not align correctly on repeated portal verifications. One of the problems with trying to adjust patient position to fit more tightly within the mask is that these attempts may modify the geometry of the entire neck region relative to the isocentre, thus resulting in misalignment of the beams in the some part of the treated volume despite a somewhat adequate isocentre alignment.

5. CONCLUSIONS
==============

In the present investigation, the beam intensities of initial [imrt]{.smallcaps} plans were applied on repeat [ct]{.smallcaps} scans obtained weekly during treatment to assess the impact of geometric uncertainties on the dose distributions for head-and-neck cancer patients treated with [imrt]{.smallcaps}. Significant deviation from the prescribed dose occurred during fractionated [imrt]{.smallcaps} treatment because of variations in patient positioning and changes in the surrounding tissue. Adding localization uncertainty margins at the time of planning to generate [ptv]{.smallcaps}s and [prv]{.smallcaps}s reduces the risk of underdosing targets and overdosing the spinal cord. However, the D~mean~ to both parotids and to the larynx tends to increase with the size of the margins added for [ptv]{.smallcaps}. Based on our findings, use of 5.0-mm [ptv]{.smallcaps} margins for the [gtv]{.smallcaps} and 2.5-mm [ptv]{.smallcaps} margins for the upper neck [ctv]{.smallcaps} achieves a satisfactory compromise between target coverage and parotid sparing.

Our results also show that, for patients treated with comprehensive nodal [imrt]{.smallcaps}, errors in shoulder repositioning can cause significant dose perturbations in the lower neck region despite the use of 5.0-mm [ptv]{.smallcaps} margins. The use of a thermoplastic mask extending down to the level of the shoulder should be considered in these patients to improve set-up reproducibility.

Finally, the concept of [ptv]{.smallcaps} and [prv]{.smallcaps} will certainly evolve with the use of inverse planning methods for [imrt]{.smallcaps}. Integration of the geometric uncertainty in the form of probabilistic algorithms in the optimization process has been proposed to maximize the probability of target coverage and [oar]{.smallcaps} sparing [@b33-co13_3p108]. Further quantification of the geometric variations and their effect on the dose distribution is essential to the development of integrated planning systems of this kind.

Figures and Tables
==================

![For this patient, elevation of the shoulder during the repeat computed tomography ([ct]{.smallcaps}) scan (right) as compared with the planning [ct]{.smallcaps} scan (left) resulted in reduced coverage of the lower neck region because of greater attenuation of the oblique beams. The effect on the prescription isodose (orange) is significant, but influence on the coverage by the 90% isodose (green) is minimal.](co13_3p108f1){#f1-co13_3p108}

###### 

Target coverage for the initial intensity modulated radiotherapy ([imrt]{.smallcaps}) plans and repeat computed tomography ([ct]{.smallcaps}) scans when 0-mm, 2.5-mm, and 5.0-mm localization uncertainty margins were used [a](#tfn1-co13_3p108){ref-type="table-fn"}

                                                      *Margins (mean % ± standard deviation)*                                                
  --------------------------------------------------- ----------------------------------------- ----------- ---------- ---------- ---------- ----------
  [gtv]{.smallcaps}                                                                                                                          
   V~100~[b](#tfn2-co13_3p108){ref-type="table-fn"}   95.7±0.7                                  85.9±9.8    95.6±0.7   96.9±4.1   95.8±1.4   99.1±1.1
   V~95~[b](#tfn2-co13_3p108){ref-type="table-fn"}    99.9±0.2                                  97.4±3.9    99.8±0.2   99.6±1.0   99.7±0.4   99.9±0.1
   D~99~[c](#tfn3-co13_3p108){ref-type="table-fn"}    98.4±0.4                                  94.0±3.2    97.9±1.1   98.5±2.3   97.8±2.0   99.9±1.3
  [ctv]{.smallcaps} upper neck                                                                                                               
   V~100~[b](#tfn2-co13_3p108){ref-type="table-fn"}   97.6±0.4                                  94.7±2.9    97.5±1.0   98.4±1.3   95.4±1.4   98.7±1.2
   V~95~[b](#tfn2-co13_3p108){ref-type="table-fn"}    99.5±0.3                                  97.9±1.6    99.3±0.5   99.5±0.5   98.1±0.5   99.7±0.3
   D~99~[c](#tfn3-co13_3p108){ref-type="table-fn"}    97.3±1.2                                  91.0±5.6    96.0±3.1   98.9±2.8   91.4±3.2   99.7±2.2
  [ctv]{.smallcaps} lower neck                                                                                                               
   V~100~[b](#tfn2-co13_3p108){ref-type="table-fn"}   96.9±1.2                                  88.3±8.3    97.9±1.0   94.8±5.6   96.1±0.4   96.8±4.4
   V~95~[b](#tfn2-co13_3p108){ref-type="table-fn"}    99.4±0.3                                  95.1±4.5    99.3±0.3   98.5±2.2   98.5±0.4   99.4±0.9
   D~99~[c](#tfn3-co13_3p108){ref-type="table-fn"}    97.0±1.6                                  85.1±10.5   98.0±1.6   95.3±5.4   90.0±7.1   98.9±3.0

For the initial [imrt]{.smallcaps} plans, values are for the planning target volume obtained by expanding the gross tumour volume ([gtv]{.smallcaps}) and clinical target volume ([ctv]{.smallcaps}) with 0 mm, 2.5 mm, and 5.0 mm localization uncertainty margins. For the repeat [ct]{.smallcaps} scans (recalculated dose distributions), the values are for the [gtv]{.smallcaps}s and [ctv]{.smallcaps}, given that the localization uncertainty margins were added for planning only.

Reported as a percentage (%) of the absolute volume.

Reported as a percentage (%) of the prescribed dose to the [gtv]{.smallcaps}s and [ctv]{.smallcaps}s.

V~100~ = 100% of the prescribed dose; V~95~ = 95% of the prescribed dose; D~99~ = the dose delivered to at least 99% of the volume.

###### 

Dose to organs at risk ([oar]{.smallcaps}s) for the initial intensity modulated radiotherapy ([imrt]{.smallcaps}) plans and repeat computed tomography ([ct]{.smallcaps}) scans when 0-mm, 2.5-mm, and 5.0-mm localization uncertainty margins were used

                          *Margins (mean Gy ± standard deviation)*                                                
  ----------------------- ------------------------------------------ ---------- ----------- ---------- ---------- ----------
  Spinal cord                                                                                                     
   D~max~                 43.1±1.4                                   45.9±3.1   45.8±0.8    44.9±2.6   46.9±0.9   43.0±3.3
   D~1cm3~                37.9±1.0                                   38.5±2.1   41.1±0.6    38.8±1.7   42.6±1.0   38.1±2.1
  Brain stem                                                                                                      
   D~max~                 40.8±8.1                                   42.1±7.4   49.5±3.9    45.6±5.9   55.6±2.6   48.4±4.0
   D~1cm3~                33.9±8.4                                   34.5±8.2   41.8±5.4    35.9±6.8   49.4±3.3   41.2±4.8
  Parotid contralateral                                                                                           
   D~mean~                24.4±0.6                                   25.9±4.0   25.6±0.5    26.7±4.4   27.7±1.5   29.2±5.4
  Parotid ipsilateral                                                                                             
   D~mean~                25.8±1.6                                   28.1±3.3   28.6±3.8    31.4±4.3   31.2±4.5   34.0±5.4
  Larynx                                                                                                          
   D~mean~                30.6±1.5                                   33.4±2.7   32.4±32.4   35.3±3.8   36.9±2.5   39.3±3.6
  Mandible                                                                                                        
   D~1cm3~                60.5±3.4                                   61.5±3.9   63.3±3.6    64.1±4.0   66.0±2.8   66.9±3.6

Values are for the planning organ-at-risk volume ([prv]{.smallcaps}) obtained by expanding the spinal cord and brain stem volume with 0 mm, 2.5 mm, and 5.0 mm localization uncertainty margins. No [prv]{.smallcaps}s were generated for the parotids, larynx, and mandible.

Values are for the spinal cord and brain-stem volume; the localization uncertainty margins were added for planning only.

D~max~ = maximum dose; D~1cm3~ = the highest dose to a volume of 1 cm^3^; D~mean~ = mean dose.

###### 

Difference [a](#tfn8-co13_3p108){ref-type="table-fn"} in the gross tumour volume ([gtv]{.smallcaps}) and clinical target volume ([ctv]{.smallcaps}) between the repeat computed tomography ([ct]{.smallcaps}) scans and the planning [ct]{.smallcaps} scans

                        *[gtv]{.smallcaps}*                          
  --------------------- --------------------- ----------- ---------- ----------
  Mean difference (%)   +1.6±3.4              −6.0±10.0   −1.3±2.6   +1.7±4.0

Percentage of the absolute volume, obtained by comparing the [gtv]{.smallcaps} and [ctv]{.smallcaps} volumes from the repeat [ct]{.smallcaps} scans with the corresponding planning [ct]{.smallcaps} scan.
